Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial

PURPOSE: TRC102, a small-molecule base-excision repair inhibitor, potentiates the cytotoxicity of pemetrexed and reverses resistance by binding to chemotherapy-induced abasic sites in DNA. We conducted a phase I clinical trial combining pemetrexed and TRC102 with cisplatin–radiation in stage III non...

Descripción completa

Detalles Bibliográficos
Autores principales: Biswas, Tithi, Dowlati, Afshin, Kunos, Charles A., Pink, John J., Oleinick, Nancy L., Malik, Shakun, Fu, Pingfu, Cao, Shufen, Bruno, Debora S., Bajor, David L., Patel, Monaliben, Gerson, Stanton L., Machtay, Mitchell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866206/
https://www.ncbi.nlm.nih.gov/pubmed/34740922
http://dx.doi.org/10.1158/1078-0432.CCR-21-2025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866206/
https://www.ncbi.nlm.nih.gov/pubmed/34740922
http://dx.doi.org/10.1158/1078-0432.CCR-21-2025

Ejemplares similares